60 DEGREES PHARMACEUTICALS, INC. 8-K — AI Bull & Bear Analysis

60 Degrees Pharmaceuticals has provided the market with a detailed look at its statistical hurdles and regulatory ambitions for tafenoquine. While the company frames the conditional power analysis as a tool for precision, it simultaneously introduces the risk of a prolonged and more expensive trial process. The filing underscores a high-stakes gamble on a rare disease indication where the reward is a fast-tracked approval, but the cost of failure is a depleted treasury. Investors are now weighing the potential for a valuation re-rating against the reality of a cash-starved biotech facing a rigorous FDA bar. The outcome of the interim analysis, scheduled for October 2026 or upon reaching 24 patients, will be the definitive signal for the company's viability. Until then, the stock remains a speculative play on both clinical efficacy and the company's ability to fund its operations through 2028.